Finding – Page 17

LB Pharma’s Novel Antipsychotic LB-102 Shows Promise in Phase II Schizophrenia Trial

10 months ago talkbio0Tagged benzamide antipsychotic, first-in-class, LB-102, PANSS, Phase 2 Clinical Trials, Schizophrenia, Score

LB-102, Benzamide antipsychotic, Schizophrenia treatment, Phase II clinical trial, PANSS score reduction, First-in-class potential

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

10 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Carecode Revolutionizes Brazilian Healthcare with AI-Powered Customer Service, Secures $4.3M Funding

10 months ago talkbio0Tagged Artificial Intelligence, Automation, brazilian, Carecode, Customer, Health care facility, Services

Carecode, AI, Healthcare, Customer Service, Automation, Funding, Brazilian Healthcare

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

10 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

10 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

10 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

Jazz Pharmaceuticals Announces CEO Succession Plan as Co-Founder Bruce Cozadd Prepares to Retire

11 months ago talkbio0Tagged biopharmaceutical company, BIRC6 gene, CEO, Cozadd, Jazz, Leadership, Retirement, Succession Plan

Jazz Pharmaceuticals, Bruce Cozadd, CEO succession plan, retirement, biopharmaceutical company, leadership transition

Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

11 months ago talkbio0Tagged Ability to perform cognitive activity, Antipsychotic Agents, Brilaroxazine, Effectiveness, Long-term, Negative, Safety, Schizophrenia, Symptoms aspect

Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning

Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

11 months ago talkbio0Tagged Affordable medication, CALR gene, Eli, Eli Lilly, Obesity, Pharmaceutical Services, Self-pay, single-dose, Telemedicine, Zepbound

Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy

Empowering Patients: The Key to Faster, More Impactful Research

11 months ago talkbio0Tagged Clinical Research, Empowerment, Engaged to be married, Health care facility, outcomes, Patient-Centered Care, Precision Medicine

Patient-centered care, Patient engagement, Personalized medicine, Clinical research, Healthcare outcomes, Patient empowerment